StemCells, Inc. (STEM: Quote) on Thursday announced the initiation of a Phase I/II clinical trial of the company's proprietary HuCNS-SC product candidate (purified human neural stem cells) in dry age-related macular degeneration or AMD referred to as Geographic Atrophy.
Dry AMD is the most common form of macular degeneration. There are no approved treatments for the condition.
The trial is being conducted at the Retina Foundation of the Southwest's Anderson Vision Research Center in Dallas, Texas.
Click here to receive FREE breaking news email alerts for StemCells Inc and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com